Emily Damone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily Damone has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Allison Mary Deal
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications - Marjory Charlot
Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
2 shared publications - Andrew Chambers
Campbell University School of Osteopathic Medicine, United States of America
1 shared publication Chenguang Wang
Regeneron Tarrytown New York USA
1 shared publicationChristina Yongue
Greensboro Health Disparities Collaborative, Greensboro, NC
1 shared publicationCleo Samuel-Ryals
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
1 shared publication
Latest Publications
- 9 October 2025
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 31 (4) , 932-949
Bayesian joint models for longitudinal, recurrent, and terminal event data
Many methods exist to jointly model either recurrent and related terminal survival events or longitudinal outcome measures and related terminal survival event. However, few methods exist which can account for the dependency between all three outcomes of interest, and none allow for the modeling of all three outcomes without strong correlation assumptions. We propose a joint model which uses subject-specific random effects to connect the survival model (terminal and recurrent events) with a longitudinal outcome model. In the proposed method, proportional hazards models with shared frailties are used to model dependence between the recurrent and terminal events, while a separate (but correlated) set of random effects are utilized in a generalized linear mixed model to model dependence with longitudinal outcome measures. All random effects are related based on an assumed multivariate normal distribution. The proposed joint modeling approach allows for flexible models, particularly for unique longitudinal trajectories, that can be utilized in a wide range of health applications. We evaluate the model through simulation studies as well as through an application to data from the Atherosclerosis Risk in Communities (ARIC) study.
- 9 October 2025
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 31 (4) , 932-949
Bayesian joint models for longitudinal, recurrent, and terminal event data
Many methods exist to jointly model either recurrent and related terminal survival events or longitudinal outcome measures and related terminal survival event. However, few methods exist which can account for the dependency between all three outcomes of interest, and none allow for the modeling of all three outcomes without strong correlation assumptions. We propose a joint model which uses subject-specific random effects to connect the survival model (terminal and recurrent events) with a longitudinal outcome model. In the proposed method, proportional hazards models with shared frailties are used to model dependence between the recurrent and terminal events, while a separate (but correlated) set of random effects are utilized in a generalized linear mixed model to model dependence with longitudinal outcome measures. All random effects are related based on an assumed multivariate normal distribution. The proposed joint modeling approach allows for flexible models, particularly for unique longitudinal trajectories, that can be utilized in a wide range of health applications. We evaluate the model through simulation studies as well as through an application to data from the Atherosclerosis Risk in Communities (ARIC) study.
- 20 February 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (5) , e70021
Jointly Modeling Time‐To‐Event and Longitudinal Data With Individual‐Specific Change Points: A Case Study in Modeling Tumor Burden
In oncology clinical trials, tumor burden (TB) stands as a crucial longitudinal biomarker, reflecting the toll a tumor takes on a patient's prognosis. With certain treatments, the disease's natural progression shows the tumor burden initially receding before rising once more. Biologically, the point of change may be different between individuals and must have occurred between the baseline measurement and progression time of the patient, implying a random effects model obeying a bound constraint. However, in practice, patients may drop out of the study due to progression or death, presenting a non‐ignorable missing data problem. In this paper, we introduce a novel joint model that combines time‐to‐event data and longitudinal data, where the latter is parameterized by a random change point augmented by random pre‐slope and post‐slope dynamics. Importantly, the model is equipped to incorporate covariates across the longitudinal and survival models, adding significant flexibility. Adopting a Bayesian approach, we propose an efficient Hamiltonian Monte Carlo (HMC) algorithm for parameter inference. We demonstrate the superiority of our approach compared to a longitudinal‐only model via simulations and apply our method to a data set in oncology. The code for implementation is publicly available on https://github.com/quyixiang/chgptModel .
- 20 February 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (5) , e70021
Jointly Modeling Time‐To‐Event and Longitudinal Data With Individual‐Specific Change Points: A Case Study in Modeling Tumor Burden
In oncology clinical trials, tumor burden (TB) stands as a crucial longitudinal biomarker, reflecting the toll a tumor takes on a patient's prognosis. With certain treatments, the disease's natural progression shows the tumor burden initially receding before rising once more. Biologically, the point of change may be different between individuals and must have occurred between the baseline measurement and progression time of the patient, implying a random effects model obeying a bound constraint. However, in practice, patients may drop out of the study due to progression or death, presenting a non‐ignorable missing data problem. In this paper, we introduce a novel joint model that combines time‐to‐event data and longitudinal data, where the latter is parameterized by a random change point augmented by random pre‐slope and post‐slope dynamics. Importantly, the model is equipped to incorporate covariates across the longitudinal and survival models, adding significant flexibility. Adopting a Bayesian approach, we propose an efficient Hamiltonian Monte Carlo (HMC) algorithm for parameter inference. We demonstrate the superiority of our approach compared to a longitudinal‐only model via simulations and apply our method to a data set in oncology. The code for implementation is publicly available on https://github.com/quyixiang/chgptModel .
- 14 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16) , 1755-1762
Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery
PURPOSE: Timely lung cancer surgery is a metric of high-quality cancer care and improves survival for early-stage non–small-cell lung cancer. Historically, Black patients experience longer delays to surgery than White patients and have lower survival rates. Antiracism interventions have shown benefits in reducing racial disparities in lung cancer treatment. METHODS: We conducted a secondary analysis of Accountability for Cancer Care through Undoing Racism and Equity, an antiracism prospective pragmatic trial, at five cancer centers to assess the impact on overall timeliness of lung cancer surgery and racial disparities in timely surgery. The intervention consisted of (1) a real-time warning system to identify unmet care milestones, (2) race-specific feedback on lung cancer treatment rates, and (3) patient navigation. The primary outcome was surgery within 8 weeks of diagnosis. Risk ratios (RRs) and 95% CIs were estimated using log-binomial regression and adjusted for clinical and demographic factors. RESULTS: A total of 2,363 patients with stage I and II non–small-cell lung cancer were included in the analyses: intervention (n = 263), retrospective control (n = 1,798), and concurrent control (n = 302). 87.1% of Black patients and 85.4% of White patients in the intervention group ( P = .13) received surgery within 8 weeks of diagnosis compared with 58.7% of Black patients and 75.0% of White patients in the retrospective group ( P < .01) and 64.9% of Black patients and 73.2% of White patients ( P = .29) in the concurrent group. Black patients in the intervention group were more likely to receive timely surgery than Black patients in the retrospective group (RR 1.43; 95% CI, 1.26 to 1.64). White patients in the intervention group also had timelier surgery than White patients in the retrospective group (RR 1.10; 95% CI, 1.02 to 1.18). CONCLUSION: Accountability for Cancer Care through Undoing Racism and Equity is associated with timelier lung cancer surgery and reduction of the racial gap in timely surgery.
- 14 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16) , 1755-1762
Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery
PURPOSE: Timely lung cancer surgery is a metric of high-quality cancer care and improves survival for early-stage non–small-cell lung cancer. Historically, Black patients experience longer delays to surgery than White patients and have lower survival rates. Antiracism interventions have shown benefits in reducing racial disparities in lung cancer treatment. METHODS: We conducted a secondary analysis of Accountability for Cancer Care through Undoing Racism and Equity, an antiracism prospective pragmatic trial, at five cancer centers to assess the impact on overall timeliness of lung cancer surgery and racial disparities in timely surgery. The intervention consisted of (1) a real-time warning system to identify unmet care milestones, (2) race-specific feedback on lung cancer treatment rates, and (3) patient navigation. The primary outcome was surgery within 8 weeks of diagnosis. Risk ratios (RRs) and 95% CIs were estimated using log-binomial regression and adjusted for clinical and demographic factors. RESULTS: A total of 2,363 patients with stage I and II non–small-cell lung cancer were included in the analyses: intervention (n = 263), retrospective control (n = 1,798), and concurrent control (n = 302). 87.1% of Black patients and 85.4% of White patients in the intervention group ( P = .13) received surgery within 8 weeks of diagnosis compared with 58.7% of Black patients and 75.0% of White patients in the retrospective group ( P < .01) and 64.9% of Black patients and 73.2% of White patients ( P = .29) in the concurrent group. Black patients in the intervention group were more likely to receive timely surgery than Black patients in the retrospective group (RR 1.43; 95% CI, 1.26 to 1.64). White patients in the intervention group also had timelier surgery than White patients in the retrospective group (RR 1.10; 95% CI, 1.02 to 1.18). CONCLUSION: Accountability for Cancer Care through Undoing Racism and Equity is associated with timelier lung cancer surgery and reduction of the racial gap in timely surgery.
- 8 October 2021
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (2) , 214-219
Social support and outcomes in older adults with lung cancer
- 8 October 2021
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 13 (2) , 214-219
Social support and outcomes in older adults with lung cancer